• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

长链非编码RNA-AC068228.1是一种新型的预后生物标志物，可促进肺腺癌的恶性表型。

LncRNA-AC068228.1 Is a Novel Prognostic Biomarker That Promotes Malignant Phenotypes in Lung Adenocarcinoma.

作者信息

Jiang Xiulin, Chen Min, Du Junyi, Bi Hong, Guo Xiang, Yang Chao, He Xu, Jin Zhixian

机构信息

The Department of Pneumology, The First People's Hospital-Calmette Hospital of Kunming, Kunming, China.

出版信息

Front Oncol. 2022 Feb 23;12:856655. doi: 10.3389/fonc.2022.856655. eCollection 2022.

DOI:10.3389/fonc.2022.856655
PMID:35280807
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8904746/
Abstract

BACKGROUND

The crucial roles played by lncRNA-AC068228.1 in primary malignant cancer remain poorly understood. This study aimed at examining the clinical significance and evaluating the biological function of AC068228.1 in lung adenocarcinoma (LUAD).

METHODS

We used data obtained from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and the Gene Expression Omnibus (GEO) database to examine the expression of AC068228.1 in LUAD patients, and the prognostic and diagnostic value of those levels. Functional experiments were conducted to determine the function of AC068228.1 on LUAD cells. Signaling pathway enrichment analysis of AC068228.1 was conducted using the clusterProfiler and Gene Set Enrichment Analysis (GSEA) software. We analyzed the correlation between AC068228.1 expression and immune infiltration level in LUAD using the single-sample gene set enrichment analysis (ssGSEA) method by the R package GSVA.

RESULTS

AC068228.1 expression was significantly elevated in LUAD tissues compared with normal tissues. Higher expression of AC068228.1 was strongly correlated with adverse clinical outcomes and was identified as an independent prognostic marker for LUAD patients. GSEA and infiltration analysis confirmed that AC068228.1 expression was significantly correlated with immune cells infiltrating in LUAD. Knockdown of AC068228.1 inhibited the cell proliferation and cell migration of LUAD.

CONCLUSIONS

AC068228.1 was upregulated in LUAD and was significantly correlated with adverse clinical outcomes. Meanwhile, it was associated with immune cell infiltration and could be used as a promising diagnostic and prognostic biomarker for LUAD patients.

摘要

背景

长链非编码RNA-AC068228.1在原发性恶性肿瘤中所起的关键作用仍知之甚少。本研究旨在探讨AC068228.1在肺腺癌（LUAD）中的临床意义并评估其生物学功能。

方法

我们使用从癌症基因组图谱（TCGA）、基因型-组织表达（GTEx）和基因表达综合数据库（GEO）获得的数据，来检测AC068228.1在LUAD患者中的表达情况，以及这些表达水平的预后和诊断价值。进行功能实验以确定AC068228.1对LUAD细胞的功能。使用clusterProfiler和基因集富集分析（GSEA）软件对AC068228.1进行信号通路富集分析。我们通过R包GSVA的单样本基因集富集分析（ssGSEA）方法，分析了AC068228.1表达与LUAD中免疫浸润水平之间的相关性。

结果

与正常组织相比，AC068228.1在LUAD组织中的表达显著升高。AC068228.1的高表达与不良临床结局密切相关，并被确定为LUAD患者的独立预后标志物。GSEA和浸润分析证实，AC068228.1的表达与LUAD中浸润的免疫细胞显著相关。敲低AC068228.1可抑制LUAD的细胞增殖和细胞迁移。

结论

AC068228.1在LUAD中上调，且与不良临床结局显著相关。同时，它与免疫细胞浸润有关，可作为LUAD患者有前景的诊断和预后生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/6bb789675d6a/fonc-12-856655-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/271cbad2c391/fonc-12-856655-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/f0288f175d8a/fonc-12-856655-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/d9eac1e6d404/fonc-12-856655-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/ffa57fc4dca5/fonc-12-856655-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/c61c1f11b376/fonc-12-856655-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/db2a97804dd1/fonc-12-856655-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/539a937775a8/fonc-12-856655-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/5b689441650e/fonc-12-856655-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/6bb789675d6a/fonc-12-856655-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/271cbad2c391/fonc-12-856655-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/f0288f175d8a/fonc-12-856655-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/d9eac1e6d404/fonc-12-856655-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/ffa57fc4dca5/fonc-12-856655-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/c61c1f11b376/fonc-12-856655-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/db2a97804dd1/fonc-12-856655-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/539a937775a8/fonc-12-856655-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/5b689441650e/fonc-12-856655-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ff/8904746/6bb789675d6a/fonc-12-856655-g009.jpg

相似文献

1
LncRNA-AC068228.1 Is a Novel Prognostic Biomarker That Promotes Malignant Phenotypes in Lung Adenocarcinoma.长链非编码RNA-AC068228.1是一种新型的预后生物标志物，可促进肺腺癌的恶性表型。
Front Oncol. 2022 Feb 23;12:856655. doi: 10.3389/fonc.2022.856655. eCollection 2022.
2
Upregulation of Long Non-Coding RNA GCC2-AS1 Facilitates Malignant Phenotypes and Correlated With Unfavorable Prognosis for Lung Adenocarcinoma.长链非编码RNA GCC2-AS1的上调促进肺腺癌的恶性表型并与不良预后相关。
Front Oncol. 2021 Jan 26;10:628608. doi: 10.3389/fonc.2020.628608. eCollection 2020.
3
Comprehensive analysis to identify GNG7 as a prognostic biomarker in lung adenocarcinoma correlating with immune infiltrates.综合分析确定GNG7作为肺腺癌中与免疫浸润相关的预后生物标志物。
Front Genet. 2022 Sep 9;13:984575. doi: 10.3389/fgene.2022.984575. eCollection 2022.
4
AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma.AUNIP表达与免疫浸润相关，是肝细胞癌和肺腺癌的候选诊断及预后生物标志物。
Front Oncol. 2020 Dec 9;10:590006. doi: 10.3389/fonc.2020.590006. eCollection 2020.
5
Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.SEC61G 在肺腺癌中的预后价值：基于生物信息学和体外验证的综合研究。
BMC Cancer. 2021 Nov 13;21(1):1216. doi: 10.1186/s12885-021-08957-4.
6
FAM207BP, a pseudogene-derived lncRNA, facilitates proliferation, migration and invasion of lung adenocarcinoma cells and acts as an immune-related prognostic factor.FAM207BP，一个假基因衍生的长非编码 RNA，促进肺腺癌细胞的增殖、迁移和侵袭，并作为一个免疫相关的预后因素。
Life Sci. 2021 Mar 1;268:119022. doi: 10.1016/j.lfs.2021.119022. Epub 2021 Jan 9.
7
ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.ECE2 是一个与 m6A 修饰相关的预后生物标志物，参与肺腺癌的免疫浸润。
Front Endocrinol (Lausanne). 2022 Oct 10;13:1013238. doi: 10.3389/fendo.2022.1013238. eCollection 2022.
8
Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma.与免疫细胞浸润相关的干扰素调节因子4可预测肺腺癌患者的预后。
Front Oncol. 2021 Jun 14;11:698465. doi: 10.3389/fonc.2021.698465. eCollection 2021.
9
CKS2 Overexpression Correlates with Prognosis and Immune Cell Infiltration in Lung Adenocarcinoma: A Comprehensive Study based on Bioinformatics and Experiments.CKS2过表达与肺腺癌预后及免疫细胞浸润的相关性：一项基于生物信息学和实验的综合研究
J Cancer. 2021 Oct 11;12(23):6964-6978. doi: 10.7150/jca.63625. eCollection 2021.
10
NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.NPM1 是肺腺癌免疫浸润的预后生物标志物，与 m6A 修饰和糖酵解有关。
Front Immunol. 2021 Jul 16;12:724741. doi: 10.3389/fimmu.2021.724741. eCollection 2021.

引用本文的文献

1
Immune infiltration and drug treatment response of angiogenesis-related LncRNA in lung adenocarcinoma.肺腺癌中血管生成相关长链非编码RNA的免疫浸润与药物治疗反应
Medicine (Baltimore). 2025 Jul 4;104(27):e42958. doi: 10.1097/MD.0000000000042958.
2
Construction of an EMT-related lncRNA prognostic signature for lung adenocarcinoma and functional verification of its hub gene LINC01615.构建 EMT 相关 lncRNA 预后signature 用于肺腺癌，并对其关键基因 LINC01615 进行功能验证。
J Cancer Res Clin Oncol. 2023 Dec;149(20):17781-17793. doi: 10.1007/s00432-023-05476-6. Epub 2023 Nov 7.
3
Comprehensive analysis to identify GNG7 as a prognostic biomarker in lung adenocarcinoma correlating with immune infiltrates.

本文引用的文献

1
DNA methylation in lung cancer patients: Opening a "window of life" under precision medicine.肺癌患者的DNA甲基化：在精准医学下开启一扇“生命之窗”
Biomed Pharmacother. 2021 Dec;144:112202. doi: 10.1016/j.biopha.2021.112202. Epub 2021 Oct 13.
2
miR-133b targets NCAPH to promote β-catenin degradation and reduce cancer stem cell maintenance in non-small cell lung cancer.微小RNA-133b靶向核仁磷酸化蛋白促进β-连环蛋白降解并减少非小细胞肺癌中癌症干细胞的维持。
Signal Transduct Target Ther. 2021 Jul 7;6(1):252. doi: 10.1038/s41392-021-00555-x.
3
Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
综合分析确定GNG7作为肺腺癌中与免疫浸润相关的预后生物标志物。
Front Genet. 2022 Sep 9;13:984575. doi: 10.3389/fgene.2022.984575. eCollection 2022.
靶向代谢以改善肿瘤微环境用于癌症免疫治疗。
Mol Cell. 2020 Jun 18;78(6):1019-1033. doi: 10.1016/j.molcel.2020.05.034.
4
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies.非小细胞肺癌信号通路、代谢与PD-1/PD-L1抗体
Cancers (Basel). 2020 Jun 5;12(6):1475. doi: 10.3390/cancers12061475.
5
Role of non-coding RNAs and RNA modifiers in cancer therapy resistance.非编码 RNA 和 RNA 修饰物在癌症治疗耐药中的作用。
Mol Cancer. 2020 Mar 2;19(1):47. doi: 10.1186/s12943-020-01171-z.
6
Long non-coding RNA in lung cancer.肺癌中的长链非编码RNA
Clin Chim Acta. 2020 May;504:190-200. doi: 10.1016/j.cca.2019.11.031. Epub 2019 Nov 29.
7
The roles of exosomal miRNAs and lncRNAs in lung diseases.外泌体 miRNAs 和 lncRNAs 在肺部疾病中的作用。
Signal Transduct Target Ther. 2019 Nov 13;4:47. doi: 10.1038/s41392-019-0080-7. eCollection 2019.
8
YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression.YTHDF1 连接缺氧适应与非小细胞肺癌进展。
Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.
9
Macrophages and Metabolism in the Tumor Microenvironment.肿瘤微环境中的巨噬细胞和代谢
Cell Metab. 2019 Jul 2;30(1):36-50. doi: 10.1016/j.cmet.2019.06.001.
10
Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update.非小细胞肺癌（NSCLC）的分子诊断与靶向治疗：最新进展
Discov Med. 2019 Mar;27(148):167-170.